Monopar Therapeutics Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Monopar Therapeutics Inc. (MNPR) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations of $52.76 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-08-12
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $52.76M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $52.54M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $61.83M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $127.68M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations |
|---|---|
| 2026-06-30 | $52.76M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $52.54M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $61.83M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $127.68M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $39.50M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $39.71M 10-Q · filed 2026-05-14 |
| 2024-12-31 | $45.82M 10-Q · filed 2026-08-12 |
| 2024-09-30 | $6.02M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $6.12M 10-Q · filed 2025-08-12 |
| 2024-03-31 | $7.81M 10-Q · filed 2025-05-13 |
| 2023-12-31 | $7.27M 10-K · filed 2026-03-27 |
| 2023-09-30 | $5.52M 10-Q · filed 2024-11-08 |
| 2023-06-30 | $7.21M 10-Q · filed 2024-08-09 |
| 2023-03-31 | $5.73M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $8.19M 10-K · filed 2025-03-31 |
| 2022-09-30 | $14.32M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $16.46M 10-Q · filed 2023-08-10 |
| 2021-12-31 | $20.30M 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |